gemcitabine has been researched along with Inflammatory Response Syndrome, Systemic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, H; Chen, Z; Geng, YW; Meng, ZQ; Qi, Q; Wang, P; Xu, LT; Yu, SL | 1 |
| Bartsch, DK; Fendrich, V; Hudemann, C; Knoop, RF; Lauth, M; Plassmeier, L; Sparn, M; Waldmann, J | 1 |
2 other study(ies) available for gemcitabine and Inflammatory Response Syndrome, Systemic
| Article | Year |
|---|---|
Serum lactate dehydrogenase predicts prognosis and correlates with systemic inflammatory response in patients with advanced pancreatic cancer after gemcitabine-based chemotherapy.
Topics: Antimetabolites, Antineoplastic; Blood Cell Count; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Lymphocyte Count; Male; Palliative Care; Pancreatic Neoplasms; Platelet Count; Prognosis; Systemic Inflammatory Response Syndrome; Treatment Outcome | 2017 |
Chronic pancreatitis and systemic inflammatory response syndrome prevent impact of chemotherapy with gemcitabine in a genetically engineered mouse model of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Cytokines; Deoxycytidine; Disease Models, Animal; Gemcitabine; Genes, p53; Genes, ras; Homeodomain Proteins; Mice; Mice, Transgenic; NF-kappa B; Pancreatic Neoplasms; Pancreatitis, Chronic; Phosphorylation; STAT3 Transcription Factor; Systemic Inflammatory Response Syndrome; Trans-Activators; Treatment Outcome | 2014 |